Pharmacogenomics Approach to Toxicity in Breast Cancer Patients Treated with Taxanes

Angelini, Silvia; Botticelli, Andrea; ONESTI, Concetta Elisa; Giusti, Raffaele; Sini, Valentina; Durante, Valeria; Strigari, Lidia; Gentile, Giovanna; Cerbelli, Bruna; Pellegrini, Patrizia; Sgroi, Valentina; Occhipinti, Mario; Di Pietro, Francesca; Rossi, Alessandro; Simmaco, Maurizio; Mazzuca, Federica; Marchetti, Paolo

doi:10.21873/anticanres.11610

Request a copy

Article (Scientific journals)

Pharmacogenomics Approach to Toxicity in Breast Cancer Patients Treated with Taxanes

Angelini, Silvia; Botticelli, Andrea; ONESTI, Concetta Elisa et al.

2017 • In Anticancer Research, 37 (5), p. 2633-2639

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/217491

DOI
10.21873/anticanres.11610

PubMed
28476838

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

taxani.pdf

Publisher postprint (118.91 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Disciplines :

Oncology

Author, co-author :

Angelini, Silvia; Università degli Studi di Roma "La Sapienza" > Medical Oncology

Botticelli, Andrea; Università degli Studi di Roma "La Sapienza" > Medical Oncology

ONESTI, Concetta Elisa ; Università degli Studi di Roma "La Sapienza" > Medical Oncology

Giusti, Raffaele; Università degli Studi di Roma "La Sapienza" > Medical Oncology

Sini, Valentina; Santo Spirito Hospital, rome, Italy > Medical Oncology

Durante, Valeria; Università degli Studi di Roma "La Sapienza" > Medical Oncology

Strigari, Lidia; IRCCS Regina Elena National Cancer Institute

Gentile, Giovanna; Istituto dermopatico dell'Immacolata, IDI-IRCCS, Rome, Italy

Cerbelli, Bruna; Università degli Studi di Roma "La Sapienza"

Pellegrini, Patrizia; Università degli Studi di Roma "La Sapienza" > Medical Oncology

More authors (7 more)

Language :

English

Title :

Pharmacogenomics Approach to Toxicity in Breast Cancer Patients Treated with Taxanes

Publication date :

May 2017

Journal title :

Anticancer Research

ISSN :

0250-7005

eISSN :

1791-7530

Publisher :

JG Delinassios Anticancer Research, Athens, Greece

Volume :

Issue :

Pages :

2633-2639

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 28 December 2017

Statistics

Number of views

41 (1 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ and Naghavi M: Breast and cervical cancer in 187 countries between 1980 and 2010: A systematic analysis. Lancet 378(9801): 1461-1484, 2011.
National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Breast Cancer, version 1, 2016. Available at URL: http://www.nccn.org/professionals/physician-gls/pdf/breast.pdf
Bines J, Earl H, Buzaid AC and Saad ED: Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: Does the sequence matter? Ann Oncol 25(6): 1079-1085, 2014.
Chan S, Friedrichs K, Noel D, Pintér T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, González Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J and 303 Study Group: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17(8): 2341-2354, 1999.
Ford HE, Yap YS, Miles DW, Makris A, Hall M, Miller L, Harries M, Smith IE and Johnston SR: A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer. Cancer Chemother Pharmacol 58(6): 809-815, 2006.
Lee JJ and Swain SM: Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24(10): 1633-1642, 2006.
Hagiwara H and Sunada Y: Mechanism of taxane neurotoxicity. Breast Cancer 11(1): 82-85, 2004.
Evans WE and McLeod HL: Pharmacogenomics-drug disposition, drug targets, and side-effects. N Engl J Med 348(6): 538-549, 2003.
Gligorov J and Lotz JP: Preclinical pharmacology of the taxanes: Implications of the differences. Oncologist 9(Suppl 2): 3-8, 2009.
Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ and Gelboin HV: Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: Enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 8(5): 391-401, 1998.
Cresteil T, Monsarrat B, Dubois J, Sonnier M, Alvinerie P and Gueritte F: Regioselective metabolism of taxoids by human CYP3A4 and 2C8: Structure-activity relationship. Drug Metab Dispos 30(4): 438-445, 2002.
van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G and Sparreboom A: Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 6(7): 2598-2603, 2000.
Bosch TM, Huitema AD, Doodeman VD, Jansen R, Witteveen E, Smit WM, Jansen RL, van Herpen CM, Soesan M, Beijnen JH and Schellens JH: Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res 12(19): 5786-5793, 2006.
Gréen H, Söderkvist P, Rosenberg P, Horvath G and Peterson C: MDR-1 single-nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 12(3 Pt 1): 854-859, 2006.
Trock BJ, Leonessa F and Clarke R: Multidrug resistance in breast cancer: A meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 89(13): 917-931, 1997.
Meier Y, Pauli-Magnus C, Zanger UM, Klein K, Schaeffeler E, Nussler AK, Nussler N, Eichelbaum M, Meier PJ and Stieger B: Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology 44: 62-74, 2006.
Thörn M, Finnström N, Lundgren S, Rane A and Lööf L: Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 60(1): 54-60, 2005.
Wang D, Johnson AD, Papp AC, Kroetz DL and Sadée W: Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15(10): 693-704, 2005.
Rollason V, Samer C, Piguet V, Dayer P and Desmeules J: Pharmacogenetics of analgesics: Toward the individualization of prescription. Pharmacogenomics 9(7): 905-933, 2005.
Kim RB: MDR1 single-nucleotide polymorphisms: Multiplicity of haplotypes and functional consequences. Pharmacogenetics 54: 592-603, 2002.
Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and Rubin P: CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3): 176-181, 2003.
Bosch TM, Meijerman I, Beijnen JH and Schellens JH: Genetic polymorphisms of drug-metabolizing enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 45: 253-285, 2006.
Kim HJ, Im SA, Keam B, Ham HS, Lee KH, Kim TY, Kim YJ, Oh DY, Kim JH, Han W, Jang IJ, Kim TY, Park IA and Noh DY: ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. Cancer Sci 106(1): 86-93, 2015.
Abraham JE, Guo Q, Dorling L, Tyrer J, Ingle S, Hardy R, Vallier AL, Hiller L, Burns R, Jones L, Bowden SJ, Dunn JA, Poole CJ, Caldas C, Pharoah PP and Earl HM: Replication of genetic polymorphisms reported to be associated with taxanerelated sensory neuropathy in patients with early breast cancer treated with paclitaxel. Clin Cancer Res 20(9): 2466-2475, 2014.
Kim KP, Ahn JH, Kim SB, Jung KH, Yoon DH, Lee JS and Ahn SH: Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy. Cancer Chemother Pharmacol 69: 1221-1227, 2012.
Leskelä S, Jara C, Leandro-García LJ, Martínez A, García-Donas J, Hernando S, Hurtado A, Vicario JC, Montero-Conde C, Landa I, López-Jiménez E, Cascón A, Milne RL, Robledo M and Rodríguez-Antona C: Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J 11: 121-129, 2011.
Bergmann TK, Brasch-Andersen C, Gréen H, Mirza MR, Skougaard K, Wihl J, Keldsen N, Damkier P, Peterson C, Vach W and Brøsen K: Impact of ABCB1 variants on neutrophil depression: A pharmacogenomic study of paclitaxel in 92 women with ovarian cancer. Basic Clin Pharmacol Toxicol 110: 199-204, 2011.
Bergmann TK, Gréen H, Brasch-Andersen C, Mirza MR, Herrstedt J, Hølund B, du Bois A, Damkier P, Vach W, Brosen K and Peterson C: Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol 67(7): 693-700, 2011.
Tsai SM, Lin CY, Wu SH, Hou LA, Ma H, Tsai LY and Hou MF: Side-effects after docetaxel treatment in Taiwanese breast cancer patients with CyP3A4, CYP3A5, and ABCB1 gene polymorphisms. Clin Chim Acta 404(2): 160-165, 2009.
Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi O, Lenz HJ, McLeod HL, Lara PN Jr, Coltman CA Jr, Fukuoka M, Saijo N, Fukushima M and Mack PC: Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A model for assessing populationrelated pharmacogenomics. J Clin Oncol 27(21): 3540-3546, 2009.
Chang H, Rha SY, Jeung HC, Im CK, Ahn JB, Kwon WS, Yoo NC, Roh JK and Chung HC: Association of the ABCB1 gene polymorphisms 2677G > T/A and 3435C > T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol 20(2): 272-277, 2009.
Marsh S, Paul J, King CR, Gifford G, McLeod HL and Brown R: Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 25(29): 4528-4535, 2007.
Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A and Mielke S: Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 42(17): 2893-2896, 2006.
De Iuliis F, Salerno G, Taglieri L and Scarpa S: Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review. Cancer Chemother Pharmacol 76(4): 679-690, 2015.
Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, Matsuo M, Kasuga M and Okumura K: Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 71(4): 297-303, 2002.
Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, Mielke S, Viganò L, Locatelli A, Verweij J, Sparreboom A and McLeod HL: Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 11(22): 8097-8104, 2005.
Gentile G, Botticelli A, Lionetto L, Mazzuca F, Simmaco M, Marchetti P and Borro M: Genotype-phenotype correlations in 5-fluorouracil metabolism: A candidate DPYD haplotype to improve toxicity prediction. Pharmacogenomics J 16(4): 320-325, 2016.